Impact of high-dose peginterferon alfa-2a on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

Abstract

This study tested the hypothesis that high-dose peginterferon alfa-2a (PEG-IFNα-2a) for the first 12 weeks would increase early and sustained virological response (SVR) rates in patients with chronic hepatitis C genotype 1. Eight hundred ninety-six patients were randomized 1:1 to 360 μg (n = 448) or 180 μg (n = 448) PEG-IFNα-2a weekly plus ribavirin at 1000-1200 mg/day for 12 weeks, followed by 36 weeks of 180 μg PEG-IFNα-2a weekly plus ribavirin at 1000-1200 mg/day with 871 patients evaluable for the intention-to-treat analysis. Virological responses were assessed by TaqMan (limit of detection 15 IU/mL) at week 4, 8, 12, 24, 48 (end of therapy), and 24 weeks following therapy (SVR). Undetec..